Please login to the form below

Not currently logged in
Email:
Password:

AZ discontinues asthma medicine

AstraZeneca is to discontinue production of an inhaled version of its asthma medication Pulmicort due to 'manufacturing issues'

AstraZeneca (AZ) is to discontinue production of the pressurised metered dose inhaler (pMDI) version of its asthma medication Pulmicort (budesonide), in both its 100µg and 200µg doses, due to 'manufacturing issues'.

The company said the problem is due to 'product-specific processes and components', the combination of which was used solely in the manufacturing of Pulmicort pMDI.

The decision to discontinue the product was not related to the active ingredient of the medicine, budesonide - a corticosteroid also used in AZ's nasal inhalant, Rhinocort, for conditions such as hayfever, and the controlled-release capsule Entocort for Crohn's disease.

Other unaffected products include AZ's Pulmicort Turbuhaler, Pulmicort Respules and Pulmicort Flexhaler.

David Smith, executive vice president, Global Operations and IS, AstraZeneca, said the company had "exhausted all potential solutions" in its efforts to solve the technical problems and to continue supplying the product.

"[I]t is in the patient's best interest to find an alternative medication as soon as possible," continued Smith, with AZ stating that it is working with regulatory authorities and healthcare professionals to help patients on Pulmicort pMDI to switch treatments.

Patients currently on the medication will be able to finish any current supplies they have remaining.

7th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics